In addition, SCLC tumors were evaluated for the expression of MHC II, emerging immune checkpoints PVR, IDO, and lymphocyte exhaustion markers, including TIM3 to allow for new trials of immune therapy in these SCLC subsets. This evidence concerns the gene HAVCR2 and small cell lung carcinoma.